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ABSTRACT
Introduction: Chronic low back pain (CLBP) produces
considerable direct costs as well as indirect burdens
for society, industry and health systems. CLBP is
characterised by heterogeneity, inclusion of several
pain syndromes, different underlying molecular
pathologies and interaction with psychosocial factors
that leads to a range of clinical manifestations. There is
still much to understand in the underlying pathological
processes and the non-psychosocial factors which
account for differences in outcomes. Biomarkers that
may be objectively used for diagnosis and
personalised, targeted and cost-effective treatment are
still lacking. Therefore, any data that may be obtained
at the ‘-omics’ level (glycomics, Activomics and
genome-wide association studies—GWAS) may be
helpful to use as dynamic biomarkers for elucidating
CLBP pathogenesis and may ultimately provide
prognostic information too. By means of a
retrospective, observational, case-cohort, multicentre
study, we aim to investigate new promising biomarkers
potentially able to solve some of the issues related
to CLBP.
Methods and analysis: The study follows a
two-phase, 1:2 case–control model. A total of 12 000
individuals (4000 cases and 8000 controls) will be
enrolled; clinical data will be registered, with particular
attention to pain characteristics and outcomes of pain
treatments. Blood samples will be collected to perform
-omics studies. The primary objective is to recognise
genetic variants associated with CLBP; secondary
objectives are to study glycomics and Activomics
profiles associated with CLBP.
Ethics and dissemination: The study is part of the
PainOMICS project funded by European Community in
the Seventh Framework Programme. The study has been
approved from competent ethical bodies and copies of
approvals were provided to the European Commission
before starting the study. Results of the study will be
reviewed by the Scientific Board and Ethical Committee
of the PainOMICS Consortium. The scientific results will
be disseminated through peer-reviewed journals.
Trial registration number: NCT02037789; Pre-results.
INTRODUCTION
Low back pain (LBP) is one of the most
common health problems worldwide with an
estimated age-standardised point prevalence
of 9.4%.1 In 2012, a global review of the
prevalence of LBP was published reporting a
mean±SEM point prevalence of activity-
limiting LBP lasting >1 day of 11.9±2.0%, and
the 1-month prevalence of 23.2±2.9%.2 LBP
accounts for considerable disability and work
absence, and ranks in the Global Burden of
Disease 2013 study as a leading contributor
to global disability measured in years lost due
to disability (YLDs).3 LBP is deﬁned as pain
Strengths and limitations of this study
▪ Multiple-centre and multiple-discipline study:
The study includes centres in the European
Union (EU), USA and Australia, with research
teams specialising in following fields: (1) clinical
aspects of pain, (2) biology and genetics of pain,
(3) generation of ‘-omics’ data and (4) analysis
of multiple ‘-omics’ data.
▪ Hypothesis driven versus hypothesis generating:
The study aims to profile ‘-omics’ biomarkers
(genome-wide association studies (GWAS), gly-
comics and Activomics) potentially to decipher
the pathogenesis of chronic low back pain
(CLBP) associated with the different patho-
physiological patterns.
▪ Longitudinal design with a large sample size: (1)
discovery phase with 3000 cases and 6000 con-
trols; (2) validation phase with 1000 cases and
2000 controls.
▪ While the heterogeneity of the study populations
is helpful in the discovery phase, this may limit
conclusions in the validation phase.
▪ Functional investigation with animal model has
not been included in the current project due to
the limitation of the funding.
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and discomfort, localised below the costal margin and
above the inferior gluteal folds, with or without leg pain.
Prognostic factors for LBP include demographic
factors (educational attainment, age and gender), occu-
pational factors (employment), mental health morbidity
(anxiety and depression), perception of pain and dis-
ability (pain intensity and expectation of persistent
pain) and other psychological factors (fear avoidance,
catastrophising, illness perceptions).4
LBP becomes chronic LBP (CLBP) when symptoms
last at least 3 months. Activity-limiting LBP tends to
recur and the course of LBP is increasingly viewed as a
chronic recurring condition,5 which accounts for consid-
erable direct economic costs as well as indirect burdens
for society, industry and health systems.6 7 The preva-
lence of chronic CLBP appears to be rising with an
increase from 3.9% in 1992 to 10.2% in 2006 in the
USA,8 and from 4.2% in 2002 to 9.6% in 2010 in Brazil.9
Pain is a subjective sensation, which is inﬂuenced by a
range of physical and psychosocial factors through
poorly understood neural mechanisms.10 The advances
in medical imaging have improved our ability to identify
the anatomic origin of CLBP; however, CLBP is hetero-
geneous and the anatomic site only tells part of the
story. There is considerable variation in prognosis and,
at present, CLBP exerts a substantial burden on the indi-
vidual, the family and workplace.
Evidence-based guidelines recommend the initial
exclusion of serious diagnosis before the implementa-
tion of clinical management, which promotes continued
function and best practice rehabilitation approaches.
However, there is much more to understand about the
underlying process, how this affects the prognosis and
how we can use this to tailor treatment for the individ-
ual. In making a diagnosis of LBP, red ﬂag symptoms are
used to identify the need for investigation for underlying
serious illness.11 Yellow ﬂags (psychosocial factors) iden-
tify risks of chronicity12 and highlight the heterogeneity
and complexity of CLBP where the severity, chronicity
and prognosis may depend on the anatomical site, the
underlying pathological process, comorbidities as well as
individual psychosocial factors.
While psychosocial factors clearly inﬂuence outcomes
in CLBP, genetic and epigenetic factors may account for
some variation in response to treatment. Even though
persistent CLBP and disc degeneration are known to be
heritable13 14 and the two traits are highly related to
one another, with disc degeneration being a major pre-
dictor for LBP episodes,14 few genetic variants have
been identiﬁed and conﬁrmed for both traits.15–17 Only
two genome-wide association studies report on chronic/
persistent widespread pain16 17 and two genome-wide
association studies (GWAS) of intervertebral disc degen-
eration.18 19 In keeping with other common complex
traits, the individual effects of the identiﬁed loci are
small and explain only a small fraction of the trait or
disease variation.20 As such, they do not substantially
improve predictions over those based on known factors
such as family history.21–23 Unfortunately, these data
have not yet shed light on the pain pathogenesis
mechanisms, and they do not offer prediction of treat-
ment likely suitable in individual patients. Replication of
these ﬁndings is also needed. Hence, despite promising
recent data, new studies are needed to identify objective
biomarkers for diagnosis and prediction of treatment’s
efﬁcacy in patients having CLBP.
Glycomics is an emerging ﬁeld, recently identiﬁed as a
priority for the next decade by the US National
Academies of Science.24 25 Recent studies reported
protein glycosylation in large human population
samples, with promising glycan proﬁling for disease
diagnosis and stratiﬁcation for example, autoimmune
diseases and haematological cancers, metabolic syn-
drome, systemic lupus erythematosus and many other
diseases.26–33 Together with glycomics, Activomics may
also provide insight via new biomarkers for LBP as it
combines data involved in enzymatic activity of several
post-translational modiﬁcation (PTM) proteins in an
integrated model, providing dynamic characterisation of
the current state of an organism.
Activomics, is a novel -omic strategy that aims to
describe biological systems in terms of differential
protein PTM activities. Perturbations in intracellular
and/or intercellular cell signalling networks are fre-
quently linked to chronic diseases such as cancer.
Enzyme activities in serum are monitored using a propri-
etary panel of protein and peptide substrates under mul-
tiple assay conditions including the judicious use of
enzyme cofactors and inhibitors in order to optimise the
discrimination between protein modiﬁcation enzymes
with preferences for overlapping primary sequence or
structural targets. Principal Activomics substrate panels
include proteases (metalloproteinases, serine, cysteine,
aspartic proteases) and their protease inhibitors (eg,
serpins), caspases, kinases (ser/thr and tyr), phospha-
tases and (de)acetylases.
Here, we present the study protocol for a retrospective
analysis, in a large cohort of patients having CLBP, to
determine ‘-omics’ biomarkers (GWAS, glycomics and
Activomics) potentially associated with susceptibility to
CLBP and with different pathophysiological patterns34 35
(see online supplementary ﬁle). Glycomic and
Activomic approaches aim to reveal alterations in prote-
ome complexity that arise from post-translational modiﬁ-
cations that vary in response to changes in the
physiological environment, a particularly important
avenue to explore in chronic inﬂammatory diseases.
Furthermore, exploring disease-related links between
glycomic and Activomic data within the context of a
clearly deﬁned genetic and demographic background is
a highly original and potentially instructive secondary
objective of the current study. Since aforementioned
studies connected mostly N-glycans with chronic inﬂam-
mation and methods for high-throughput glycoprotein
analysis are still in development, our glycomic data will
be based exclusively on released N-glycans.
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This study will link clinical data to the multiple
‘-omics’ analyses, thereby proﬁling novel biomarkers,
which have strong potential to advance our knowledge
of some of the remaining unsolved problems in CLBP.
The present manuscript serves to describe the regis-
tered protocol in order to disseminate the rationale, the
methods and the main aims of the clinical study.
METHODS
We present a retrospective observational, multicentre,
international clinical study, with a case–control design.
We describe the details of the retrospective cohort
protocol clinical study without providing any preliminary
results. Patient enrolment is currently active, up to
September 2016. The study is part of the PainOMICS
project that includes four different trials and was
reviewed and funded by European Community in the
Seventh Framework Programme (FP7)—THEME
(HEALTH.2013.2.2.1-5—Understanding and controlling
pain).
The project includes six clinical centres from Italy,
Croatia, Belgium, Australia and the USA, and four
centres for scientiﬁc analyses from Croatia, France,
Germany and UK. Statistical expertise is provided by the
‘PolyOmica’ consulting based in the Netherlands.
The retrospective study was approved by the ethical
committees of each separate clinical centre between
December 2013 and March 2014.
The study is registered at Clinicaltrials.gov
(NCT02037789).
Participant enrolment and data collection
Cases (patients having CLBP) will be enrolled by each
participating centre (ﬁgure 1). Every effort will be made
to accumulate a well-characterised cohort of patients
with persistent CLBP, subgrouped according to the likely
anatomical cause of the pain. Patients fulﬁlling the fol-
lowing conditions will be considered for enrolment: age
18 years and older; chronic pain (pain lasting longer
than 12 weeks) between the costal margins and gluteal
fold, with or without symptoms in one or both legs,
written informed consent signed and Caucasian
ancestry.
Controls (patients without CLBP) will be retrieved
from two different sources: (1) existing biobanks of
healthy participants having collected information about
CLBP; (2) participants enrolled in the parallel prospect-
ive study on acute LBP (part of PainOMICS project—
NCT 02037763), that is, patients who presented with
acute LBP and have not become chronic over 6 months
Figure 1 Study flow chart. CRF,
Case Report Form; LBP, low back
pain.
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but the pain has resolved. Age (decades) and gender
distribution of controls will be matched as closely as pos-
sible to that of the cases. Controls are enrolled accord-
ing to the following inclusion criteria: older than
18 years, no chronic pain (lasting longer than 12 weeks)
in the past 12 months, written informed consent
obtained and Caucasian ancestry.
Participants with any evidence of clinically unstable
disease, severe psychiatric disorder (excluding mild depres-
sion) or mental impairment; recent history (<1 year) of
spinal fracture, back pain due to spinal tumour or infec-
tion, pregnancy, will be excluded from the study.
Patients and controls selected for participation will
receive a detailed description of the study and will be
asked to sign an informed consent prior to entering the
study (enrolment visit).
Once enrolled in the trial, patients will be assigned to
a unique anonymous code. Data collection includes;
demographics (age, gender, race, body mass index
(BMI), occupational history), clinical and pharmaco-
logical history, pain characteristics (onset, duration,
intensity, pain referral pattern, irradiation, sensory
abnormalities, precipitating events, history of previous
episodes), effectiveness/tolerability of pain treatments
received (when applicable). A speciﬁc questionnaire
(Pain-DETECT (PD)) is applied to evaluate pain type
and the pain generator, as well as the possible patho-
physiological (nociceptive and/or neuropathic) mechan-
ism sustaining CLBP and functional impairment.
Blood samples for -omics analyses are taken from each
enrolled patient at the time of the enrolment consult-
ation, and biological samples are sent to analytical part-
ners of the consortium for speciﬁc -omics analysis.
Clinical data are collected in the designated ad-hoc
Case Report Form and into a dedicated web database
(Research Electronic Data Capture (REDCap)); access
to the web database is restricted to the project partners
and can be accessed using a dedicated username and a
password.
-Omics data are centralised in a speciﬁc supervised
database.
Samples collection methodology
All the clinical centres have to guarantee that the bio-
logical samples from each patient will be prepared,
stored and shipped following the analytical procedures
described in three standard operating procedures
(SOPs) developed and validated to provide details for
conducting the study, phase by phase, with written
instructions to achieve uniformity of the procedures
used for obtaining patient blood for -omic analysis tech-
niques, storing the samples and shipping the aliquots to
the specialised laboratories.
All the patients and controls undergo blood sampling
for -omics determinations. The samples will be collected
into two tubes containing EDTA for genetic and glyco-
mic analyses and into one serum tube with clot activator
plus gel for the Activomics. For genetic analyses, DNA
will be isolated from whole blood samples using a com-
mercial DNA extraction kit.
Detailed description of the validation of SOPs is pro-
vided in a separate paper under submission.
Analyses for biologic markers
Genetic analyses
GWAS analyses will be performed on DNA samples iso-
lated from whole blood, using genome-wide Illumina
genotyping technology.36 37 Brieﬂy, 4 µL of 60 ng/µL
DNA will be ampliﬁed at 37°C overnight, followed by
enzymatic fragmentation, alcohol precipitation and
DNA resuspension. Whole genome ampliﬁed DNA will
be hybridised to the Illumina HumanCore BeadChip,
including >240 000 genome-wide tag single nucleotide
polymorphisms (SNPs) and >20 000 high-value markers
(indels and updated exome-focused content). After
hybridisation, allelic speciﬁcity will be conferred by
enzymatic base extension. Products will be subsequently
stained, and the intensities of the beads’ ﬂuorescence
will be detected by the iScan System (Illumina)
Genotype calling will be performed with the Illumina
GenomeStudio 2011.1 Genotyping Module 1.9.4 soft-
ware. During quality control genotype data will be ﬁl-
tered by sample-wise and variant-wise call rates and by
Hardy-Weinberg Eqilibrium p values. Related indivi-
duals, individuals with extreme heterozygosity rates and
individuals whose genetics suggest non-Caucasian
origins will be discarded. A much denser set of markers
will be obtained by genotype imputation using the
Haplotype Reference Consortium (HRC) reference
panel. The resulting set of markers will contain geno-
types measured on the Illumina chip and genotypes
imputed based on the very dense HRC reference panel.
For each genetic variant, a standard association model
(linear or logistic regression model) will be used to
investigate associations between CLBP-related pheno-
types and genetic markers. The problem of multiple
testing will be addressed by judging the signiﬁcance of
associations using a Bonferroni-corrected, genome-wide
signiﬁcance level corresponding to a nominal signiﬁ-
cance level of 5%.
Glycomics analyses
Glycomics analyses will be performed on total serum
proteins and on a single serum protein, immunoglobu-
lin G (IgG). IgG will be isolated from serum samples by
afﬁnity chromatography using 96-well monolithic plates
with Protein G as previously described (Pucic et al, MCP,
2011). N-glycans will be released from total serum
proteins and IgG by overnight deglycosylation with
N-glycosidase F (PNGase F). Released N-glycans will be
ﬂuorescently labelled with 2-aminobenzamide (2-AB)
ﬂuorescent tag and puriﬁed by hydrophilic interaction
liquid chromatography (HILIC) solid phase extraction
(SPE). Labelled N-glycans will be analysed by hydro-
philic interaction chromatography on a Waters Acquity
UPLC instrument using Waters BEH Glycan
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chromatography column, 100 mM ammonium formate,
pH 4.4, as solvent A and acetonitrile as solvent B. The
system will be calibrated using an external standard of
hydrolysed and 2-AB-labelled glucose oligomers from
which the retention times for the individual glycans will
be converted to glucose units. Data processing will be
performed with an automatic processing method after
which each chromatogram will be manually corrected to
maintain the same intervals of integration for all the
samples. The chromatograms obtained will all be sepa-
rated in the same manner into peaks and the amount of
glycans in each peak will be expressed as percentage of
total integrated area.
Activomics analyses
Activomics analyses will be performed on retrospective
serum samples from anonymous but well-characterised
patients. Samples are collected, handled and analysed in
a way that minimises freeze–thaw cycles and arrayed with
the aid of an automatic liquid handler robot
(MultiPROBE II, Perkin Elmer) in 96-well microtitre
plates for high throughput screening using microﬂuidic
mobility shift assays. For each enzymatic reaction tested,
2 μL of serum from patients and healthy controls will be
incubated with the appropriate Activomics substrate
under controlled conditions (time, temperature, opti-
mised buffer conditions, etc). In general, the ﬂuorescent
peptides to be used as target substrates are synthesised
through the addition of an N-terminal carboxyﬂuores-
cein (FAM) group via an aminohexanoic acid (Ahx)
spacer group, that is, FAM-Ahx-peptide. High through-
put screening is performed using a modiﬁcation of the
capillary electrophoretic mobility shift assay on an auto-
mated microﬂuidic platform (EZ Reader, Perkin Elmer,
USA). Peptide substrates are generally C-terminally ami-
dated and puriﬁed by HPLC to >90% purity (GenScript,
Hong Kong). All lyophilised peptides are redissolved in
sterile, double distilled water at 2 mM concentration and
are diluted to 10 µM for screening tests. Assays are per-
formed in the appropriate reaction buffer in 384-well
format (Corning 3821 BC) using a semiautomated pipet-
tor system for reproducibility (Sorensen Multi (Sorenson
Benchtop 96/384 semi-automated pipettor) precision
coefﬁcient of variation (CV) <5%). Post-translationally
modiﬁed products are separated from unreacted sub-
strate by high voltage microﬂuidic mobility shift assays
using voltage and pressure parameters optimised for
each substrate. Product conversion is assessed from the
respective peak areas obtained from electrophoretic
mobility shifts (% product/substrate+product). The
extent of PTM of each substrate is assessed and compared
in a univariate analysis for patients with chronic versus
those without LBP. The assays will be repeated for a panel
of different substrates in order to provide a wide view of
disease-related changes to PTM activities for multivariate
statistical analysis. Performance characteristics of the panel
will be assessed by univariate and multivariate hierarchical
clustering and principal component analysis to
differentiate activities of disease versus control samples.
Sensitivity and speciﬁcity will be evaluated in receiver oper-
ator characteristic (ROC) analyses to deﬁne cut-off values
in the design of the optimal predictive biomarker panel.
Primary and secondary objectives
The primary objective of this retrospective study is to
recognise genetic variants associated with persistent
CLBP, by comparing patients having CLBP and pain-free
patients. We will correlate genetic variants associated
with CLBP through a GWAS study, in a wide inter-
national population of European ancestry.
Secondary objectives are to recognise glycomic and
Activomic data associated with patients having CLBP
compared to patients without CLBP.
The participating clinical centres have deﬁned a
minimal shared diagnostic data set available in all clin-
ical centres. Each of the participants will stratify patients
according to their clinical features, imaging data and
results from PD. Considering the patient’s response to
diagnostic procedures, patients will be subgrouped
(taking into account the patient history, clinical examin-
ation, radiological results and potentially the response to
diagnostic blocks) into six main categories:
1. spinal stenosis,
2. discogenic pain,
3. facet joint pain,
4. sacroiliac joint pain,
5. LBP with radicular pain (not predominant radicular
pain),
6. widespread LBP.
Statistics
Study design
The study will follow a two-phase (discovery and valid-
ation), 1:2 case–control model:
▸ Discovery population: random sample of two-thirds of
the entire population of cases.
▸ Validation population: the remaining one-third.
Following the GWAS phase, the genes discovered will
be assessed for biological plausibility and entered
into the validation phase.
Sample size calculation
Since, to date, no data on the -omics of CLBP are avail-
able in literature, and since the variants associated with
most common diseases have modest effects, we consi-
dered a number of scenarios, ranging in model assump-
tions with respect to allele frequency and effect.
With 3000 cases and 6000 controls, we assessed
genetic scenarios in which we have 80% power to detect
association at genome-wide signiﬁcant level.38 Consistent
with the literature, for high ORs (=2), we will be able to
detect variants with low minor allele frequency
(MAF≥1.5%). With higher allele frequency, we will be
able to ﬁnd smaller effects; for example, for variants
with MAF=25%, we have power to detect OR≥1.25.
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For the replication/validation phase, with 1000 cases
and 2000 controls, we have 80% power to conﬁrm
detected variants when using nominal p=0.005 (leading
to experiment-wise type I error of 0.05 assuming 10
tests) and ∼60% power in case of more severe multiple
testing (100 tests, leading to nominal p=0.0005).
Statistical analysis
All the enrolled patients and controls will be analysed.
Discovery phase
For analyses investigating highly dimensional -omics
space, we will use a range of approaches. The ﬁrst
approach will extend the classical sequential framework.
Predictor screening will be performed by logistic or Cox
regression models traversing through the -omics space
and incorporating few predictors at a time. Statistically
signiﬁcant (at experiment-wise level) predictors will be
included in the model, and the next iteration through
the -omics space will be performed. A classic example of
this approach includes genome-wide association analysis,
followed by conditional analyses for identiﬁcation of sec-
ondary signals. To investigate a large numbers of predic-
tors simultaneously, we will use modern regularisation/
shrinkage and machine learning methods allowing ana-
lysis of (relatively) large numbers of predictors jointly.
While this type of approach does not address the ques-
tion of statistical testing in the same way as ‘classical’
approaches do, it is widely used in the context of bio-
marker discovery, where prediction and not the p values
are of primary interest. For all methods aimed towards
biomarker discovery, the accuracy of prediction will be
accessed by cross-validation, and optimal solutions will
be analysed to identify potential biomarkers, which will
be selected on their discriminative value in an ROC
analysis.
Validation phase
The discovered genetic variants will be examined bioin-
formatically for biological plausibility before entering
the validation phase. The association of the candidate
polymorphisms with the outcome (being a case) will be
assessed with logistic regression. The following strategies
will be used: single genes assessment/genetic score
(sum of candidate genes)/multiple genes. Adjustment
for covariates (age, gender, clinical features) will be
performed.
Details of the statistical analyses will be provided in the
ﬁnal statistical analysis plan (SAP).
The analysis of the secondary endpoints will follow the
same principles reported above.
Ethical issues
Sample collection and use of clinical data have been
started only after the ethical approval of the present
study protocol from the competent ethical bodies
(ethics committees of the institutions involved in
patients’ enrolment).
The Scientiﬁc Board and Ethical Committee of
PainOMICS Consortium will also review the results of
the study in order to evaluate any possible societal
impact of our ﬁndings according to the ethical concerns
about genetics/-omics and diagnosis of chronic pain.39
Monitoring and quality assessment
Patients will be withdrawn from the study in case of with-
drawal of consent (participants may always without obli-
gation withdraw their informed consent), or any other
condition that, on clinical judgement of the investigator,
will make unacceptable further study participation for
that individual patient.
The Coordinating Investigator (University Hospital of
Parma, Italy) will delegate, in each participating centre,
a clinical supervisor (to ensure that the study is con-
ducted according to the protocol, good clinical practice
and national regulations) and also a data monitor to
ensure accuracy, completeness and veriﬁcation of
patients’ data. The data monitors, from each participat-
ing centre, will make up the data monitoring committee.
The External Project Advisory Committee (EPAC) of the
PainOMICS FP7 project will perform an overall scientiﬁc
supervision of the trial and of the emergent data.
The participating members will discuss results and any
issues of the study at regular audits during the annual
Study in Multidisciplinary Pain Research (SIMPAR)
meeting and in any other case that may be deemed
necessary.
CONCLUSIONS
This study is, to the best of our knowledge, the ﬁrst to
investigate genetic and -omic biomarkers in a large
population sample of CLPB patients. These biomarkers
may be related to pain sensation, as well as to disease
pathophysiology and pain generators. The overall object-
ive is to validate associations that may result in a more
personalised diagnosis and therapy of a disease with a
high health and societal burden such as LBP.
Furthermore, the novel biomarkers emerging from
this retrospective study will be validated in a prospective
cohort collected within the same PainOMICS project in
order to evaluate their ability to predict the possibility of
advancement to chronic pain in patients suffering from
an acute episode of LBP.
A possible bias could be also related to the fact that in
some patients, pain could be still related to acute inﬂam-
mation even though pain was lasting since >3 months.
However, as we enrol all patients evaluated in chronic
pain services who were referred after several pharmaco-
logical therapies, we think that this bias will be limited
also by the high number of patients enrolled.
The PainOMICS project is expected to signiﬁcantly
expand the level of knowledge on how LBP is generated,
propagated and quenched. We will mobilise signiﬁcant
human and material resources in Europe and USA, allow-
ing a comprehensive characterisation of large cohorts of
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patients with CLPB, aiming to identify a number of
potential biomarkers related to different aspects of CLBP,
as well as potential new targets for therapy.
With this protocol, we would like to investigate better
biomarkers related to CLBP. The next mandatory step
will be to evaluate if and how these biomarkers could
help to predict patients at higher risk of developing
chronic pain after an acute episode, and how these bio-
markers might also be related to predicting response to
pharmacological/surgical treatment. The same research
group is already conducting a new prospective study
investigating the transition from acute to CLBP and the
enrolment will be closed in the spring 2017.
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33. Vučković F, Krištic ́ J, Gudelj I, et al. Association of systemic lupus
erythematosus with decreased immunosuppressive potential of the
IgG glycome. Arthritis Rheumatol 2015;67:2978–89.
34. Freidin MB, Lauc G, Allegri M, et al. Using omics in chronic pain
conditions to delineate mechanisms and provide new therapeutic
strategies. Pain Manag 2016;6:211–15.
35. Freidin MB, Keser T, Gudelj I, et al. The association between low
back pain and composition of IgG glycome. Sci Rep 2016;6:26815.
36. Scott RA, Lagou V, Welch RP, et al. Large-scale association
analyses identify new loci influencing glycemic traits and provide
insight into the underlying biological pathways. Nat Genet
2012;44:991–1005.
37. Schaefer AS, Bochenek G, Jochens A, et al. Genetic evidence for
PLASMINOGEN as a shared genetic risk factor of coronary artery
disease and periodontitis. Circ Cardiovasc Genet 2015;8:159–67.
38. Pe’er I, Yelensky R, Altshuler D, et al. Estimation of the multiple
testing burden for genomewide association studies of nearly all
common variants. Genet Epidemiol 2008;32:381–5.
39. Compagnone C, Tagliaferri F, Allegri M, et al. Ethical issues in pain
and omics research. Some points to start the debate. Croat Med J
2014;55:1–2.
8 Allegri M, et al. BMJ Open 2016;6:e012070. doi:10.1136/bmjopen-2016-012070
Open Access
group.bmj.com on November 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
longitudinal study
low back pain: protocol of a retrospective 
'Omics' biomarkers associated with chronic
and Guido Fanelli
Yurii S Aulchenko, Lennart C Karssen, Leonardo Kapural, Richard Rauck 
Skelin,Klaas Buyse, Gordan Lauc, Ivan Gudelj, Dragan Primorac, Andrea 
Pemberton, Jane MacDougall, Frances MK Williams, Jan Van Zundert,
Klersy, Wei Wang, Moira Sim, Christian Gieger, Judith Manz, Iain K 
Massimo Allegri, Manuela De Gregori, Cristina E Minella, Catherine
doi: 10.1136/bmjopen-2016-012070
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/10/e012070
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/10/e012070
This article cites 35 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (513)Research methods
 (384)Patient-centred medicine
 (99)Genetics and genomics
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 22, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
